



MAIL STOP PCT

Attorney Docket: 27048U

Date: February 15, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
BARU, et al.

Art Unit: ~~Unknown~~ 1654
Examiner: ~~Unknown~~ J. Ha

Serial No.: 10/553,357

Filed: October 14, 2005

International Application: PCT/IL04/00327

International Filing Date: April 15, 2004

Title: **PHARMACEUTICAL COMPOSITION COMPRISING PROTEINS AND/OR
POLYPEPTIDES AND COLLOIDAL PARTICLES**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

[XXX] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

[] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.

The enclosed statement is accompanied by [check one]:

[] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or

[] ii. a check in the amount required by 37 C.F.R. 1.17(p).

MAIL STOP PCT
Attorney Docket: 27048U
Serial No.: 10/553,357

☐ c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.
☐ Certification report(e) below; and
☐ a check in the amount as required by 1.17(p).

☐ d. The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.

☐ e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

☐ I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

☐ I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

☐ Appropriate certification is attached.

[XXX] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

[XXX] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

MAIL STOP PCT
Attorney Docket: 27048U
Serial No.: 10/553,357

or

[] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:


and / or

[XXX] Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES PLLC




Gary M. Nath, Reg. No. 26,965
Susanne M. Hopkins, Reg. No. 33,247
Customer No. 34375

NATH & ASSOCIATES PLLC
112 South West Street
Alexandria, VA 22314
GMN/SMH/le

IAP7 Rec'd PCT/PTO 15 FEB 2006

PCT



MAIL STOP PCT

Attorney Docket: 27048U

Date: February 15, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
BARU, et al.

Art Unit: ~~Unknown~~ 1654
Examiner: ~~Unknown~~ J. Hn

Serial No.: 10/553,357

Filed: October 14, 2005

International Application: PCT/IL04/00327

International Filing Date: April 15, 2004

Title: PHARMACEUTICAL COMPOSITION COMPRISING PROTEINS AND/OR
POLYPEPTIDES AND COLLOIDAL PARTICLES

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and
Trademark Office is the following:

- 1) Information Disclosure Statement;
- 2) PTO Form-1449 with 8 cited References;
- 3) Copy for 6 of the 8 cited References.

The Commissioner is hereby authorized to charge any
deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,
NATH & ASSOCIATES PLLC

Gary M. Nath, Reg. No. 26,965

Susanne M. Hopkins, Reg. No. 33,247

Customer No. 20529

NATH & ASSOCIATES PLLC
112 South West Street
Alexandria, VA 22314
GMN/SMH/le

1 FEB 15 2006

MAIL STOP PCT

Attorney Docket: 27048U

FORM PTO 1449

INFORMATION DISCLOSURE CITATION

In re Application of:
BARU, et al.Art Unit:
~~Unknown~~ 1654Serial No:
10/553,357Filed:
October 14, 2005Examiner:
~~Unknown~~
J. Ha

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Issue / Publication Date	Inventor	Filed
/J.H./	A1	4,348,384	7 Sep. 1982	Horikoshi, et al.	7 Oct. 1981
/J.H./	A2	5,013,556	7 May 1991	Woodle, et al.	20 Oct. 1989
	A3				
	A4				

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Publication Date	Country	Translation
/J.H./	A5	0 689 428 B1	3 Jan. 1996	EP	N/A
	A6	80/01456 A1	24 Jul. 1980	WO	N/A
	A7	98/32466 A1	30 Jul. 1998	WO	N/A
	A8	99/55306 A1	4 Nov. 1999	WO	N/A
	A9	02/086117 A1	31 Oct. 2002	WO	N/A
	A10				
	A11				
	A12				
	A13				
	A14				
	A15				
	A16				
	A17				
	A18				
	A19				
	A20				

OTHER

Examiner Initial		(Including Author, Title, Date, Pertinent Pages, etc.)
/J.H./	A21	Barrowcliffe, T.W., et al., "Binding to phospholipids protects factor VIII from inactivation by human antibodies", <u>J. Lab. Clin. Mes.</u> , Vol. 101, No. 1, Pages 34-43, (1983).
	A22	
	A23	

Examiner

/Julie Ha/

Date Considered

Feb. 15, 2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.